Crispr Therapeutics (NASDAQ:CRSP) was upgraded by equities researchers at William Blair from a “market perform” rating to an “outperform” rating in a research note issued to investors on Tuesday, November 19th, MarketBeat reports.
Several other brokerages also recently weighed in on CRSP. BidaskClub upgraded shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, November 15th. Barclays raised their target price on shares of Crispr Therapeutics from $59.00 to $62.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 30th. Oppenheimer upgraded shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating and set a $65.00 price objective for the company in a research note on Tuesday, November 12th. BTIG Research lifted their price objective on Crispr Therapeutics from $51.00 to $59.00 and gave the stock a “positive” rating in a report on Tuesday, July 30th. Finally, Chardan Capital reiterated a “buy” rating and issued a $72.50 price target on shares of Crispr Therapeutics in a research report on Monday, November 18th. Two analysts have rated the stock with a sell rating, two have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. Crispr Therapeutics has an average rating of “Buy” and a consensus target price of $69.54.
CRSP stock traded down $1.39 during trading on Tuesday, hitting $70.71. 1,076,777 shares of the company’s stock were exchanged, compared to its average volume of 703,067. The business has a 50-day moving average price of $54.12 and a two-hundred day moving average price of $47.22. Crispr Therapeutics has a 52-week low of $22.22 and a 52-week high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $3.95 billion, a price-to-earnings ratio of -20.56 and a beta of 3.30.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. On average, equities research analysts anticipate that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.
In related news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the sale, the director now owns 7,500 shares of the company’s stock, valued at $412,500. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 56,118 shares of company stock valued at $3,620,760. Company insiders own 21.40% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Nikko Asset Management Americas Inc. raised its position in shares of Crispr Therapeutics by 324.3% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock worth $88,143,000 after buying an additional 1,430,364 shares in the last quarter. ARK Investment Management LLC boosted its stake in Crispr Therapeutics by 34.7% during the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after purchasing an additional 701,332 shares in the last quarter. Orbimed Advisors LLC acquired a new position in shares of Crispr Therapeutics during the 3rd quarter valued at $21,167,000. Price T Rowe Associates Inc. MD raised its stake in shares of Crispr Therapeutics by 19.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after buying an additional 121,176 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after buying an additional 116,540 shares in the last quarter. 49.81% of the stock is owned by institutional investors.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: What are municipal bonds?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.